These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 32807895)
21. Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2. He J; Tao H; Yan Y; Huang SY; Xiao Y Viruses; 2020 Apr; 12(4):. PubMed ID: 32290077 [TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]
23. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
24. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. Fantini J; Chahinian H; Yahi N Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32862840 [TBL] [Abstract][Full Text] [Related]
25. Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity. Drew ED; Janes RW BMC Mol Cell Biol; 2020 Jul; 21(1):49. PubMed ID: 32611313 [TBL] [Abstract][Full Text] [Related]
26. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease. Tsuji M FEBS Open Bio; 2020 Jun; 10(6):995-1004. PubMed ID: 32374074 [TBL] [Abstract][Full Text] [Related]
27. Targeting SARS-CoV-2 RBD Interface: a Supervised Computational Data-Driven Approach to Identify Potential Modulators. Gulotta MR; Lombino J; Perricone U; De Simone G; Mekni N; De Rosa M; Diana P; Padova A ChemMedChem; 2020 Oct; 15(20):1921-1931. PubMed ID: 32700795 [TBL] [Abstract][Full Text] [Related]
29. In silico ADMET and molecular docking study on searching potential inhibitors from limonoids and triterpenoids for COVID-19. Vardhan S; Sahoo SK Comput Biol Med; 2020 Sep; 124():103936. PubMed ID: 32738628 [TBL] [Abstract][Full Text] [Related]
30. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach. Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648 [TBL] [Abstract][Full Text] [Related]
31. Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells. Baig MS; Alagumuthu M; Rajpoot S; Saqib U Drugs R D; 2020 Sep; 20(3):161-169. PubMed ID: 32592145 [TBL] [Abstract][Full Text] [Related]
32. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2. Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426 [TBL] [Abstract][Full Text] [Related]
33. Examining sialic acid derivatives as potential inhibitors of SARS-CoV-2 spike protein receptor binding domain. Banerjee T; Gosai A; Yousefi N; Garibay OO; Seal S; Balasubramanian G J Biomol Struct Dyn; 2024 Aug; 42(12):6342-6358. PubMed ID: 37424217 [TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. Hosoki K; Chakraborty A; Sur S J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257 [TBL] [Abstract][Full Text] [Related]
35. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. Zhu Y; Yu D; Yan H; Chong H; He Y J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627 [TBL] [Abstract][Full Text] [Related]
37. Combating sars-cov-2 through lipoxins, proteasome, caveolin and nuclear factor-κb pathways in non-pregnant and pregnant populations. Celik O; Celik N; Aydin S; Baysal B; Aydin S; Saglam A; Gursu Y; Dalkilic S; Ulas M; Ozcil MD; Tayyar AT; Cengiz F; Ugur K; Akkoc RF; Ersahin AA Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):221-229. PubMed ID: 32538775 [TBL] [Abstract][Full Text] [Related]
38. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Poduri R; Joshi G; Jagadeesh G Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111 [TBL] [Abstract][Full Text] [Related]
39. Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors. Romeo A; Iacovelli F; Falconi M Virus Res; 2020 Sep; 286():198068. PubMed ID: 32565126 [TBL] [Abstract][Full Text] [Related]
40. The Utility of Native MS for Understanding the Mechanism of Action of Repurposed Therapeutics in COVID-19: Heparin as a Disruptor of the SARS-CoV-2 Interaction with Its Host Cell Receptor. Yang Y; Du Y; Kaltashov IA Anal Chem; 2020 Aug; 92(16):10930-10934. PubMed ID: 32678978 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]